| 0.3931 -0.118 (-23.15%) | 03-27 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.61  |
1-year : | 0.74 |
| Resists | First : | 0.52 |
Second : | 0.63 |
| Pivot price | 0.54 |
|||
| Supports | First : | 0.33 |
Second : | 0.27 |
| MAs | MA(5) : | 0.5 |
MA(20) : | 0.56 |
| MA(100) : | 0.81 |
MA(250) : | 0.91 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 11.7  |
D(3) : | 11.4 |
| RSI | RSI(14): 18.5 |
|||
| 52-week | High : | 1.64 | Low : | 0.33 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ IINN ] has closed below the lower bollinger band by 34.8%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ IINN ] is to continue within current trading range. Bollinger Bands are 11.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.5 - 0.5 | 0.5 - 0.51 |
| Low: | 0.33 - 0.33 | 0.33 - 0.33 |
| Close: | 0.39 - 0.39 | 0.39 - 0.4 |
Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation (MV) for the treatment of respiratory failure. Its lead product is the augmented respiration technology system (ART), a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. The company was incorporated in 2018 and is based in Ra'annana, Israel.
Thu, 26 Mar 2026
Inspira Technologies Ends Bio-View Deal, Strengthens Nasdaq Compliance as 2025 Loss Narrows Growth Path - tipranks.com
Thu, 26 Mar 2026
Inspira Technologies Reports Full Year 2025 Financial Results and Provides Business Updates - The Manila Times
Thu, 26 Mar 2026
Inspira Technologies (Nasdaq: IINN) adds capital and ends Bio-View deal - Stock Titan
Thu, 26 Mar 2026
Going-concern doubts and Nasdaq pressure for Inspira Technologies (NASDAQ: IINN) - Stock Titan
Thu, 26 Mar 2026
After first patient use, Inspira lines up $49.5M in hospital orders - Stock Titan
Thu, 26 Mar 2026
Inspira Technologies Creates Wholly Owned Subsidiary for Medical Business Reorganization - tipranks.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 43 (M) |
| Held by Insiders | 2.794e+007 (%) |
| Held by Institutions | 6.6 (%) |
| Shares Short | 284 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.252e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 503.4 % |
| Return on Equity (ttm) | -114.4 % |
| Qtrly Rev. Growth | 289000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -147.89 |
| EBITDA (p.s.) | 873.36 |
| Qtrly Earnings Growth | -0.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 18 |
| Dividend | 0 |
| Forward Dividend | 637840 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|